GC Green Cross Cell Receives GMP Approval for Korea’s Largest Cell Therapy Manufacturing Facility

[Asia Economy, reporter Hyunyi Cho] On May 20, GC Green Cross Cell announced that its 'Cell Center,' the largest cell therapy manufacturing facility in Korea, located in Yongin, Gyeonggi Province, has been approved by the Ministry of Food and Drug Safety as a facility compliant with Good Manufacturing Practice (GMP) standards.

The Cell Center, completed in 2018, has a total floor area of 2,820 square meters (approximately 6,300 pyeong), consisting of two underground floors and four above-ground floors. It is equipped with state-of-the-art equipment and production facilities optimized for cell therapy manufacturing. An advanced computerized system for management and production has also been introduced, meeting global standards.

GC (Green Cross Holdings) and GC Green Cross Cell invested approximately 110 billion KRW in the facility, of which 70 billion KRW was allocated to securing equipment and infrastructure optimized for cell therapy production and research and development.

With this approval, GC Green Cross Cell can now produce approximately 20,000 packs of the anticancer cell therapy 'Immuncell-LC' annually at the Cell Center. The current GMP facility in Gasan-dong, Seoul, is scheduled to be fully integrated and relocated to the Yongin Cell Center by the second half of this year.

The company plans to actively expand its contract manufacturing organization (CMO) business for biopharmaceuticals, including cell therapies.

Lee Deukjoo, CEO of GC Green Cross Cell, stated, "With the Cell Center's manufacturing approval, we have secured production capacity for Immuncell-LC and expect improvements in productivity as well as long-term cost reduction. Through our state-of-the-art production facility, we will manufacture cell therapies that meet global standards for safety and quality."

This content was produced with the assistance of AI translation services.